Ironwood Pharmaceuticals | IRWD - Gross Profit On Sales

Stock Price
3.67
Daily Change
0.17 4.86%
Monthly
-16.97%
Yearly
462.54%
Q2 Forecast
3.51

Ironwood Pharmaceuticals reported $85.24M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Almirall EUR 429.87M 180.02M Dec/2025
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amarin USD 23.17M 961K Dec/2025
Ardelyx USD 114.37M 8.02M Dec/2025
Astellas Pharma JPY 444.26B 12.55B Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
Charles River Laboratories USD 279.32M 7.36M Mar/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Moderna USD -566M 792M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
Pacira USD 126.64M 15.61M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Takeda JPY 688.84B 101.71B Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024